A Combined Single and Multiple Ascending Dose Phase 1a/1b, Double-blind, Placebo-Controlled, and Food-effect Study to Evaluate the Safety and Pharmacokinetics of Oral KM-023 in Healthy Participants. Followed by a 3-month Open Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral KM-023 in Olmsted Syndrome Patients
Latest Information Update: 23 Oct 2026
At a glance
- Drugs Ontivatrep (Primary)
- Indications Congenital disorders; Palmoplantar keratoderma; Skin disorders
- Focus Adverse reactions; First in man
- Sponsors Orvida Pharma
Most Recent Events
- 14 Oct 2026 According to an Orvida Pharma media release, topline results from Phase 1b clinical trial in patients with Olmsted syndrome anticipated around year-end 2026.
- 15 Sep 2026 According to an Orvida Pharma media release, topline results are expected in the fourth quarter of 2026.
- 22 May 2026 Planned End Date changed from 11 Feb 2026 to 21 Nov 2026.